Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

TY - JOUR

T1 - Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

AU - Teitsma, Xavier M.

AU - Jacobs, Johannes W.G.

AU - De Jong, Pascal H.P.

AU - Hazes, Johanna M.W.

AU - Weel, Angelique E.A.M.

AU - Welsing, Paco M.J.

AU - Pethö-Schramm, Attila

AU - Borm, Michelle E.A.

AU - Van Laar, Jacob M.

AU - Bijlsma, Johannes W.J.

AU - Lafeber, Floris P.J.G.

N1 - Funding Information: Competing interests The department of the authors who included patients (JWGJ and JWJB) in the U-Act-Early trial received reimbursements from Roche Nederland BV. JWJB reported grants and fees from Roche, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and UCB. JMvL received fees from Arthrogen, MSD, Pfizer, Eli Lilly and BMS and research grants from Astra Zeneca and Roche-Genentech. FPJGL reports grants from Roche. AP-S is an employee of F Hoffmann-La Roche, and MEAB is an employee of Roche Nederland BV. Funding Information: The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer. Funding Information: Funding The U-Act-Early trial was funded by Roche Nederland BV and the work within the tREACH trial was supported by an unrestricted grant from Pfizer.

PY - 2019/1/1

Y1 - 2019/1/1

KW - DMARDs (synthetic)

KW - methotrexate

KW - rheumatoid arthritis

UR - https://www.scopus.com/pages/publications/85052952905

U2 - 10.1136/annrheumdis-2018-213767

DO - 10.1136/annrheumdis-2018-213767

M3 - Letter

C2 - 30158123

AN - SCOPUS:85052952905

SN - 0003-4967

VL - 78

SP - 142

EP - 144

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -